Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Debt Issuances (2020)

Syndax Pharmaceuticals (SNDX) has disclosed Long-Term Debt Issuances for 1 consecutive years, with $19.7 million as the latest value for Q1 2020.

For Q1 2020, Long-Term Debt Issuances changed N/A year-over-year to $19.7 million; the TTM value through Dec 2020 reached $19.7 million, changed N/A, while the annual FY2020 figure was $19.7 million, N/A changed from the prior year.
Long-Term Debt Issuances hit $19.7 million in Q1 2020 for Syndax Pharmaceuticals.
Across five years, Long-Term Debt Issuances topped out at $19.7 million in Q1 2020 and bottomed at $19.7 million in Q1 2020.